Docoh
Loading...

LOGC LogicBio Therapeutics

News

From Benzinga Pro
Barclays Maintains Overweight on LogicBio Therapeutics, Lowers Price Target to $8
17 Nov 21
News, Price Target, Analyst Ratings
Barclays analyst Gena Wang maintains LogicBio Therapeutics (NASDAQ:LOGC) with a Overweight and lowers the price target from $24 to $8.
JMP Securities Maintains Market Outperform on LogicBio Therapeutics, Lowers Price Target to $16
16 Nov 21
News, Price Target, Analyst Ratings
JMP Securities analyst Silvan Tuerkcan maintains LogicBio Therapeutics (NASDAQ:LOGC) with a Market Outperform and lowers the price target from $17 to $16.
Looking Into LogicBio Therapeutics's Return On Capital Employed
15 Nov 21
Earnings
According to data from Benzinga Pro, during Q3, LogicBio Therapeutics's (NASDAQ:LOGC) reported sales totaled $2.12 million. Despite a 2.71% increase in earnings, the company posted a loss of $9.94 million.
LogicBio Therapeutics Q3 EPS $(0.31) Up From $(0.34) YoY
15 Nov 21
Earnings, News
LogicBio Therapeutics (NASDAQ:LOGC) reported quarterly losses of $(0.31) per share. This is a 8.82 percent increase over losses of $(0.34) per share from the same period last year.
LogicBio Therapeutics To Present Data On GeneRide At European Society Of Gene And Cell Therapy (ESGCT) Virtual Congress 2021
21 Oct 21
Biotech, News, Events, General
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy
LogicBio Therapeutics Announces Early Clinical Trial Results From Phase 1/2 SUNRISE Trial Demonstrating 'measurable levels of albumin-2A'
18 Oct 21
Biotech, News, FDA, General
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children. Early data from